World First Comprehensive Risk Test-Breast & Ovarian Cancer
Filed with ASX · · 3 pages · English
Melbourne, Australia, 3 February 2023: Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”) a global leader in genomics-based tests in health, wellness and serious disease, is pleased to announce the Company will launch a ‘World First’ Comprehensive Risk Assessment Test which evaluates a women’s risk of developing Breast and/or Ovarian Cancer either from a hereditary genetic mut
Genetic Technologies Limited on 6ix
Story so far
Earlier from Genetic Technologies
- GTG to form Strategic Alliance with global leader QIAGEN
- Appendix 4C and Quarterly Business Update December 2022
- Colorectal Cancer Model Presented at ASCOGI Cancer Symposium
- GeneType Published in PLUS ONE for CVD & Type 2 Diabetes
- AGM Presentation and Chairmans Address
Later from Genetic Technologies
- Genetic Technologies Announces US$5M Registered Direct Offer
- Supplementary Announcement - Comprehensive Risk Test
- Business Update - February 2023
- Publication Highlights geneType Outperforms Current Models
- Receipt of R&D Tax Incentive Refund for geneType Multi Test
Follow Genetic Technologies into a list and get an email when it puts out news.
Follow Genetic Technologies